<DOC>
	<DOCNO>NCT01762293</DOCNO>
	<brief_summary>Famitinib tyrosin-inhibitor agent target c-Kit , VEGFR2 , PDGFR , VEGFR3 , Flt1 Flt3 , 's anti-angiogenesis effect view preclinical test . Phase I study show toxicity manageable . The purpose study determine whether Famitinib improve progression free survival compare placebo patient advance colorectal cancer fail previous least two line chemotherapy .</brief_summary>
	<brief_title>A Study Famitinib Patients With Advanced Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<criteria>Histologically cytologic confirm recurrent and/or metastatic CRC previously receive least two line standard therapy failure ( must include 5Fu , irinotecan oxaliplatin ) At least one measurable lesion , large 10 mm diameter spiral CT scan ( scan layer ≤ 5 mm ) age ≥ 18 ≤ 70 ECOG 01 Life expectancy 3 month More 4 week operation , chemotherapy , radiotherapy , cytotoxic agent tyrosine kinase inhibitor Signed date informed consent Willingness ability comply schedule visit , treatment plan , laboratory test , study procedure . Before time , second malignancy except cure basal cell carcinoma skin carcinoma insitu uterine cervix Prior therapy tyrosine kinase inhibitor agent target VEGFR , PDGFR cKit ( e.g sorafenib , sunitinib , regorafenib ) Any factor influence usage oral administration Having obvious gastrointestinal hemorrhagic tendency Known Spinal Cord compression disease brain pia mater CT /MRI screen Organ tumor overload Inadequate hepatic , renal , heart , hematologic function ( hemoglobin ≤ 90g/L , platelet ≤ 100×10^9/L , neutrophil ≤ 1.5×10^9/L , total bilirubin ≥ 1.25×the upper limit normal ( ULN ) , serum transaminase ≥ 1.5×ULN ( If liver metastasis , serum transaminase≥ 2.5×ULN ) , creatinine clearance rate ≤ 60ml/min , cholesterol ≥ 1.5×ULN triglyceride≥ 2.5 x ULN , LVEF : &lt; 50 % Preexisting uncontrolled hypertension define 140/90 mmHg despite use single medical therapy , cla s I ( NCI CTCAE 3.0 ) myocardial ischemia , arrhythmia , cardiac insufficiency urinary protein≥ ++ 24hour urinary protein ≥ 1.0 g Longterm untreated wound fracture Blood coagulation abnormal , hemorrhagic tendency Within 1 year first treatment occur artery / venous thromboembolic event , cerebral vascular accident ( include transient ischemic attack ) , deep vein thrombosis pulmonary embolism , etc . Application anticoagulant vitamin K antagonist warfarin , heparin analogue ; If prothrombin time international normalize ratio ( INR ) ≤ 1.5 , purpose prevention , use small dos warfarin ( 1mg orally , daily ) lowdose aspirin ( 80mg 100mg daily ) allow Female : All subject surgically sterile postmenopausal must agree commit use reliable method birth control duration study 6 month last dose test article . Child bear potential , negative urine serum pregnancy test result initiate Famitinib . Male : All subject surgically sterile postmenopausal must agree commit use reliable method birth control duration study 6 month last dose test article . Preexisting thyroid dysfunction , even use medical therapy , thyroid function maintain normal range Abuse psychiatric drug dysphrenia Less 4 week last clinical trial Ascites need treatment Immunodeficiency : HIV positive , acquire immunodeficiency , congenital immunodeficiency , organ transplantation Evidence significant medical illness investigator 's judgment substantially increase risk associate subject 's participation completion study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>CRC</keyword>
	<keyword>Famitinib</keyword>
	<keyword>Phase II</keyword>
	<keyword>Colorectal Cancer</keyword>
</DOC>